Subsequently, clinical trials evaluated fully human anti-CTLA-4 blocking antibodies in patients with advanced cancers, revealing a durable response in a certain proportion of patients, irrespective of the relatively high frequency of associated toxicity. Here, CTLA4 is linked to cancer.